4-hydroxyphenylpyruvate dioxygenase · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-144-hydroxyphenylpyruvate dioxygenase shows approved-linked disease relevance led by tyrosinemia. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P32754. Start with tyrosinemia, then reuse UniProt P32754 as the stable protein anchor across project notes and exports.
Start with tyrosinemia, then reuse UniProt P32754 as the stable protein anchor across project notes and exports.
4-hydroxyphenylpyruvate dioxygenase shows approved-linked disease relevance led by tyrosinemia. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with tyrosinemia because it currently carries approved-linked support. Linked drugs include NITISINONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxy4-hydroxyphenylpyruvate dioxygenase
Review this target as 4-hydroxyphenylpyruvate dioxygenase, mapped to UniProt P32754. Sequence length is 393 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats 4-hydroxyphenylpyruvate dioxygenase as ChEMBL target CHEMBL1861, mapped to UniProt P32754. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether 4-hydroxyphenylpyruvate dioxygenase is the right protein anchor across sources, using UniProt P32754 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why tyrosinemia is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | 4-hydroxyphenylpyruvate dioxygenase |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P32754 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | 4-hydroxyphenylpyruvate dioxygenase |
| UniProt Accession | P32754 |
| Component Type | Protein |
| Sequence Length | 393 aa |
4-hydroxyphenylpyruvate dioxygenase
Review this target as 4-hydroxyphenylpyruvate dioxygenase, mapped to UniProt P32754. Sequence length is 393 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
4-hydroxyphenylpyruvate dioxygenase shows approved-linked disease relevance led by tyrosinemia. 2 more disease programs remain visible in the same review block.
Start review with tyrosinemia because it currently carries approved-linked support. Linked drugs include NITISINONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3342603 | 8.0 | Ki | 10.0 | Preclinical |
| CHEMBL3343183 | 7.96 | Ki | 11.0 | Preclinical |
| CHEMBL3342605 | 7.89 | Ki | 13.0 | Preclinical |
| CHEMBL3342604 | 7.85 | Ki | 14.0 | Preclinical |
| CHEMBL3342432 | 7.82 | Ki | 15.0 | Preclinical |
| CHEMBL3342610 | 7.75 | Ki | 18.0 | Preclinical |
| CHEMBL3342431 | 7.72 | Ki | 19.0 | Preclinical |
| CHEMBL3342602 | 7.7 | Ki | 20.0 | Preclinical |
| CHEMBL3408320 | 7.68 | IC50 | 21.0 | Preclinical |
| CHEMBL3342598 | 7.66 | Ki | 22.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 4 | 68 | 6.7 |
| single protein format | 2 | 45 | 7.2 |